Recent antidiabetic drugs including GLP-1 receptor agonists and DPP-IV inhibitors have demonstrated protective effects in several cardiovascular diseases but their effect in abdominal aortic aneurysm (AAA) is far less known. AAA can be associated with extremely high rates of mortality and pharmacological treatments are still lacking underlining the real need to identify new therapeutic targets. The aim of this review was to summarize current knowledge on the role of GLP-1 pathway in AAA. A systematic literature review was performed and 6 relevant studies (2 clinical and 4 experimental) were included. Experimental studies demonstrated a protective effect of both GLP-1 receptor agonists and DPP-IV inhibitors through targeting the main pathophysiological mechanisms underlying AAA formation. The effects of these drugs in human AAA are still poorly known. In the limelight of clinical and experimental studies, we discuss current limits and future directions.

最近的抗糖尿病药物，包括GLP-1受体激动剂和DPP-IV抑制剂，已在几种心血管疾病中显示出保护作用，但其在腹主动脉瘤（AAA）中的作用却鲜为人知。AAA可能会导致极高的死亡率，并且仍然缺乏药物治疗，这突显了确定新治疗靶标的真正需求。这篇综述的目的是总结关于GLP-1途径在AAA中的作用的当前知识。进行了系统的文献综述，并包括6项相关研究（2项临床研究和4项实验研究）。实验研究表明，通过靶向AAA形成的主要病理生理机制，GLP-1受体激动剂和DPP-IV抑制剂均具有保护作用。这些药物对人类AAA的影响仍然知之甚少。在临床和实验研究的关注下，我们讨论了当前的局限性和未来的发展方向。